MMR News (1 article)
|
|
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia. Tasigna surpassed Glivec in every measure of treatment efficacy designated in the trial including prevention of disease progression at 12 months[1] . At 12-month milestone, significantly fewer patients progressed to accelerated or blastic phase on Tasigna 300 mg twice daily than on Glivec 400... Published on 9 December 2009, 04:27 |
|
|
Top Categories
We have launched our peer- reviewed, Open-access journal: Insciences Journal
Recently added
27.11.12
Consequential Life Cycle Assessment of Nitrogen Fertilisers Based on Biomass – a Swedish perspective
08.11.12
From Molecular Hollows to Imprinting Strategies – Mass-Sensitive Devices in Host-Guest Chemistry
26.04.12
CdSe/ZnSe Quantum-Dot Semiconductor Optical Amplifiers
23.03.12
Screen-printed Electrochemical Sensors and Biosensors for Monitoring Metal Pollutants